

Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

Published on 06/03/2021

COVID-19 Genomics and Precision Public Health Weekly Update Content

- Pathogen and Human Genomics Studies
- Non-Genomics Precision Health Studies
- News, Reviews and Commentaries

Pathogen and Human Genomics Studies

- COVID-19 mass testing: harnessing the power of wastewater epidemiology (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1252)
SF Fitzgerald et al, MEDRXIV, May 26, 2021

In Scotland, wastewater testing has been expanded to cover 75% of the population, with sub-catchment sampling being used to focus surge testing. SARS-CoV-2 variant detection, assessment of vaccination on community transmission and surveillance for other infectious diseases represent promising future applications.

- COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1253)
KD Myers et al, AJPM, May 25, 2021

Our analyses confirm that pre-existing ASCVD is associated with increased risk of acute myocardial infarction in the setting of COVID-19. Additionally, we establish that both diagnosed and probable FH are associated with increased risk for AMI in the setting of COVID-19. Critically, our data indicate that those with both ASCVD and FH are at very high risk of AMI if they contract COVID-19.

- Genetics of symptom remission in outpatients with COVID-19. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1254)
Dubé Marie-Pierre et al. Scientific reports 2021 5 (1) 10847

We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; $P = 4.94 \times 10^{-8}$) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission.

- Genetics of symptom remission in outpatients with COVID-19. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1255)
Dubé Marie-Pierre et al. Scientific reports 2021 5 (1) 10847

We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; $P = 4.94 \times 10^{-8}$) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission.

- SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1256)
Geers Daryl et al. Science immunology 2021 5 (59)

this study shows that some variants can partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2

vaccination, but S-specific CD4+ T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.

- Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1257)

Becker Matthias et al. Nature communications 2021 5 (1) 3109

- Blood DNA methylation and COVID-19 outcomes. (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1258)

Balnis Joseph et al. Clinical epigenetics 2021 5 (1) 118

Among COVID-19-positive patients, worse outcomes were associated with a prevailing hyper-methylated status. Recursive feature elimination identified 77 differentially methylated positions predictive of COVID-19 severity measured by the GRAM-risk score.

- Minor allele of Intercellular adhesion molecule-1 (ICAM-1) polymorphism (rs5498 1462A>G) is associated with SARS-CoV-2 infection and related mortality. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1260)

Padhi Sunali et al. The Journal of infectious diseases 2021 5

- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1262)

Sahin Ugur et al. Nature 2021 5

We extend our previous phase 1/2 trial report2 and present BNT162b2 prime/boost induced immune response data from a second phase 1/2 trial in healthy adults (18-55 years of age). BNT162b2 elicited strong antibody responses, with SARS-CoV-2 serum 50% neutralizing geometric mean titers up to 3.3-fold above those observed in COVID-19 human convalescent samples (HCS) one week post-boost.

- TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2.

(/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1266)

Trimarco Joseph D et al. PLoS pathogens 2021 5 (5) e1009599

We report the identification and validation of an ER-resident host protein, TMEM41B, as an essential host factor for not only HCoV-229E but also genetically distinct coronaviruses including the pandemic beta-coronavirus SARS-CoV-2. We show that the protein is required at an early, but post-receptor engagement, stage of the viral lifecycle.

- The UGT2A1/UGT2A2 locus is associated with COVID-19-related anosmia (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1275)

JF Shelton et al, MEDRXIV, May 31, 2021

We ran a trans-ethnic genome-wide association study (GWAS) comparing loss of smell or taste (n=47,298) with no loss of smell or taste (n=22,543) among those with a positive SARS-CoV-2 test result. We identified an association (rs7688383) in the vicinity of the UGT2A1 and UGT2A2 genes (OR=1.115, p-value=4x10⁻¹⁵), which have been linked to olfactory function. These results may shed light on the biological mechanisms underlying COVID-19 related anosmia.

- Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1277)

Chen Yuxin et al. The Lancet. Infectious diseases 2021 5

Non-Genomics Precision Health Studies

- COVID-19 mass testing: harnessing the power of wastewater epidemiology (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1252)

SF Fitzgerald et al, MEDRXIV, May 26, 2021

In Scotland, wastewater testing has been expanded to cover 75% of the population, with sub-catchment sampling being used to focus surge testing. SARS-CoV-2 variant detection, assessment of vaccination on community transmission and surveillance for other infectious diseases represent promising future applications.

- COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD

(/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1253)

KD Myers et al, AJPM, May 25, 2021

Our analyses confirm that pre-existing ASCVD is associated with increased risk of acute myocardial infarction in the setting of COVID-19. Additionally, we establish that both diagnosed and probable FH are associated with increased risk for AMI in the setting of COVID-19. Critically, our data indicate that those with both ASCVD and FH are at very high risk of AMI if they contract COVID-19.

- Genetics of symptom remission in outpatients with COVID-19. (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1254)

Dubé Marie-Pierre et al. Scientific reports 2021 5 (1) 10847

We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; $P = 4.94 \times 10^{-8}$) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission.

- Genetics of symptom remission in outpatients with COVID-19. (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1255)

Dubé Marie-Pierre et al. Scientific reports 2021 5 (1) 10847

We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; $P = 4.94 \times 10^{-8}$) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission.

- SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1256)

Geers Daryl et al. Science immunology 2021 5 (59)

this study shows that some variants can partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but S-specific CD4+ T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.

- Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1257)

Becker Matthias et al. Nature communications 2021 5 (1) 3109

- Blood DNA methylation and COVID-19 outcomes. (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1258)

Balnis Joseph et al. Clinical epigenetics 2021 5 (1) 118

Among COVID-19-positive patients, worse outcomes were associated with a prevailing hyper-methylated status. Recursive feature elimination identified 77 differentially methylated positions predictive of COVID-19 severity measured by the GRAM-risk score.

- Minor allele of Intercellular adhesion molecule-1 (ICAM-1) polymorphism (rs5498 1462A>G) is associated with SARS-CoV-2 infection and related mortality. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1260)

Padhi Sunali et al. The Journal of infectious diseases 2021 5

- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1262)

Sahin Ugur et al. Nature 2021 5

We extend our previous phase 1/2 trial report2 and present BNT162b2 prime/boost induced immune response data from a second phase 1/2 trial in healthy adults (18-55 years of age). BNT162b2 elicited strong antibody responses, with SARS-CoV-2 serum 50% neutralizing geometric mean titers up to 3.3-fold above those observed in COVID-19 human convalescent samples (HCS) one week post-boost.

- TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2.

(/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1266)

Trimarco Joseph D et al. PLoS pathogens 2021 5 (5) e1009599

We report the identification and validation of an ER-resident host protein, TMEM41B, as an essential host factor for not only

HCoV-229E but also genetically distinct coronaviruses including the pandemic beta-coronavirus SARS-CoV-2. We show that the protein is required at an early, but post-receptor engagement, stage of the viral lifecycle.

- The UGT2A1/UGT2A2 locus is associated with COVID-19-related anosmia (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1275)
JF Shelton et al, MEDRXIV, May 31, 2021

We ran a trans-ethnic genome-wide association study (GWAS) comparing loss of smell or taste (n=47,298) with no loss of smell or taste (n=22,543) among those with a positive SARS-CoV-2 test result. We identified an association (rs7688383) in the vicinity of the UGT2A1 and UGT2A2 genes (OR=1.115, p-value=4x10⁻¹⁵), which have been linked to olfactory function. These results may shed light on the biological mechanisms underlying COVID-19 related anosmia.

- Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1277)
Chen Yuxin et al. The Lancet. Infectious diseases 2021 5

News, Reviews and Commentaries

- COVID-19 mass testing: harnessing the power of wastewater epidemiology (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1252)
SF Fitzgerald et al, MEDRXIV, May 26, 2021

In Scotland, wastewater testing has been expanded to cover 75% of the population, with sub-catchment sampling being used to focus surge testing. SARS-CoV-2 variant detection, assessment of vaccination on community transmission and surveillance for other infectious diseases represent promising future applications.

- COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1253)
KD Myers et al, AJPM, May 25, 2021

Our analyses confirm that pre-existing ASCVD is associated with increased risk of acute myocardial infarction in the setting of COVID-19. Additionally, we establish that both diagnosed and probable FH are associated with increased risk for AMI in the setting of COVID-19. Critically, our data indicate that those with both ASCVD and FH are at very high risk of AMI if they contract COVID-19.

- Genetics of symptom remission in outpatients with COVID-19. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1254)
Dubé Marie-Pierre et al. Scientific reports 2021 5 (1) 10847

We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10⁻⁸) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission.

- Genetics of symptom remission in outpatients with COVID-19. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1255)
Dubé Marie-Pierre et al. Scientific reports 2021 5 (1) 10847

We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10⁻⁸) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission.

- SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1256)
Geers Daryl et al. Science immunology 2021 5 (59)

this study shows that some variants can partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but S-specific CD4+ T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.

- Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1257)

Becker Matthias et al. Nature communications 2021 5 (1) 3109

- Blood DNA methylation and COVID-19 outcomes. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1258)

Balnis Joseph et al. Clinical epigenetics 2021 5 (1) 118

Among COVID-19-positive patients, worse outcomes were associated with a prevailing hyper-methylated status. Recursive feature elimination identified 77 differentially methylated positions predictive of COVID-19 severity measured by the GRAM-risk score.

- Minor allele of Interleukin 1 (IL-1) polymorphism (rs5498 1462A>G) is associated with SARS-CoV-2 infection and related mortality. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1260)

Padhi Sunali et al. The Journal of infectious diseases 2021 5

- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1262)

Sahin Ugur et al. Nature 2021 5

We extend our previous phase 1/2 trial report2 and present BNT162b2 prime/boost induced immune response data from a second phase 1/2 trial in healthy adults (18-55 years of age). BNT162b2 elicited strong antibody responses, with SARS-CoV-2 serum 50% neutralizing geometric mean titers up to 3.3-fold above those observed in COVID-19 human convalescent samples (HCS) one week post-boost.

- TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1266)

Trimarco Joseph D et al. PLoS pathogens 2021 5 (5) e1009599

We report the identification and validation of an ER-resident host protein, TMEM41B, as an essential host factor for not only HCoV-229E but also genetically distinct coronaviruses including the pandemic beta-coronavirus SARS-CoV-2. We show that the protein is required at an early, but post-receptor engagement, stage of the viral lifecycle.

- The UGT2A1/UGT2A2 locus is associated with COVID-19-related anosmia (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1275)

JF Shelton et al, MEDRXIV, May 31, 2021

We ran a trans-ethnic genome-wide association study (GWAS) comparing loss of smell or taste (n=47,298) with no loss of smell or taste (n=22,543) among those with a positive SARS-CoV-2 test result. We identified an association (rs7688383) in the vicinity of the UGT2A1 and UGT2A2 genes (OR=1.115, p-value=4x10⁻¹⁵), which have been linked to olfactory function. These results may shed light on the biological mechanisms underlying COVID-19 related anosmia.

- Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1277)

Chen Yuxin et al. The Lancet. Infectious diseases 2021 5

Disclaimer: Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

Page last reviewed: Oct 1, 2020

Page last updated: Jun 04, 2021

Content source: Office of Genomics and Precision Public Health (<http://www.cdc.gov/genomics/>), CDC Office of Science (<https://www.cdc.gov/od/science/index.htm>)